As of Mar 30
| +0.01 / +0.47%|
The 2 analysts offering 12-month price forecasts for BioLine RX Ltd have a median target of 9.25, with a high estimate of 10.50 and a low estimate of 8.00. The median estimate represents a +328.24% increase from the last price of 2.16.
The current consensus among 2 polled investment analysts is to Buy stock in BioLine RX Ltd. This rating has held steady since March, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.